Chemo and targeted drug before surgery for HER2-positive upper tract cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of chemotherapy (gemcitabine) and a targeted drug (Trastuzumab Rezetecan) before surgery to remove the kidney and ureter. It may help shrink the tumor and improve outcomes for people with HER2-positive upper tract urothelial cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with upper tract urothelial cancer (cancer in the kidney or ureter) that is locally advanced but not spread far.
- Your cancer tests positive for HER2 (a protein that helps cancer grow) with a score of 2+ or 3+.
- You are eligible for and willing to have surgery to remove the affected kidney and ureter.
- Your overall health is reasonably good (able to care for yourself, no severe heart problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
This trial tests whether giving chemotherapy before surgery can improve outcomes for people with high-risk cancer in the upper urinary tract (the tubes that carry urine from the kidneys to the bladder). The chemotherapy is given before the standard surgery to remove the affected kidney and ureter.
This trial tests a combination of two drugs (trastuzumab rezetecan and adebrelimab) plus radiation to the bladder, aiming to preserve the bladder instead of removing it. It's for people with muscle-invasive bladder cancer that shows a specific marker called HER2.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
Hear when a new UTUC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.